Filtered By:
Drug: Fluoxetine

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 187 results found since Jan 2013.

Should This Patient With Ischemic Stroke Receive Fluoxetine?
Publication date: December 2015 Source:PM&R, Volume 7, Issue 12 Author(s): Heidi Schambra, Brian Im, Michael W. O'Dell
Source: PMandR - December 18, 2015 Category: Rehabilitation Source Type: research

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

Should This Patient With Ischemic Stroke Receive Fluoxetine?
You admit T.R., a 75-year-old man, to your inpatient rehabilitation unit 10 days after a stroke. He has a medical history of hypertension and type II diabetes. On the day of his admission to the neurology service, he experienced a sudden onset of severe left-sided weakness with a facial droop and slurring of speech. His husband was driving them both to a social event at the time and detoured immediately to the emergency department, where the patient received tissue plasminogen activator (tPA) for a large, right middle cerebral artery thrombosis seen on magnetic resonance imaging.
Source: PM and R - December 1, 2015 Category: Rehabilitation Authors: Heidi Schambra, Brian Im, Michael W. O'Dell Tags: Point/Counterpoint Source Type: research

Alterations of the Ceramide Metabolism in the Peri-Infarct Cortex Are Independent of the Sphingomyelinase Pathway and Not Influenced by the Acid Sphingomyelinase Inhibitor Fluoxetine.
Abstract Ceramides induce important intracellular signaling pathways, modulating proliferation, migration, apoptosis, and inflammation. However, the relevance of the ceramide metabolism in the reconvalescence phase after stroke is unclear. Besides its well-known property as a selective serotonin reuptake inhibitor, fluoxetine has been reported to inhibit the acid sphingomyelinase (ASM), a key regulator of ceramide levels which derives ceramide from sphingomyelin. Furthermore, fluoxetine has shown therapeutic potential in a randomized controlled rehabilitation trial in stroke patients. Our aim was to investigate an...
Source: Neural Plasticity - November 27, 2015 Category: Neurology Authors: Brunkhorst R, Friedlaender F, Ferreirós N, Schwalm S, Koch A, Grammatikos G, Toennes S, Foerch C, Pfeilschifter J, Pfeilschifter W Tags: Neural Plast Source Type: research

Fluoxetine Enhances Neurogenesis in Aged Rats with Cortical Infarcts, but This is not Reflected in a Behavioral Recovery
Abstract Age is associated with poor outcome and impaired functional recovery after stroke. Fluoxetine, which is widely used in clinical practice, can regulate hippocampal neurogenesis in young rodents. As the rate of neurogenesis is dramatically reduced during aging, we studied the effect of post-stroke fluoxetine treatment on neurogenesis in the subventricular zone (SVZ) and subgranular zone (SGZ) of dentate gyrus (DG) and whether this would be associated with any behavioral recovery after the cortical infarct in aged rats. Aged rats were randomly assigned to four groups: sham-operated rats, sham-operated rats t...
Source: Journal of Molecular Neuroscience - October 16, 2015 Category: Neuroscience Source Type: research

The ms-smart trial in secondary progressive multiple sclerosis: a multi-arm, multi-centre trial of neuroprotection
There is currently no treatment for secondary progressive multiple sclerosis (SPMS) which determines the majority of disability in multiple sclerosis. The MS-SMART trial is a multi-arm, multi-centre, phase 2 randomised trial for patients with SPMS. A total of 440 patients with progressing SPMS will be recruited in England and Scotland and randomised to one of 4 blinded arms: amiloride 5mg bd, riluzole 50mg bd, fluoxetine 20mg bd or placebo. These agents have been chosen after an extensive systematic review which has suggested putative neuroprotective properties. Patients will be followed up for 96 weeks with outcome data c...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Chataway, J., Chandran, S., Miller, D., Giovannoni, G., Wheeler-Kingshott, C., Pavitt, S., Stallard, N., Hawkins, C., Sharrack, B., for the MS-SMART trialists Tags: Immunology (including allergy), Multiple sclerosis, Stroke, Radiology, Radiology (diagnostics) Thur 21, Parallel session 5: Therapeutics Source Type: research

Autism in the Son of a Woman with Mitochondrial Myopathy and Dysautonomia: A Case Report
Conclusion Given emerging evidence that mitochondrial dysfunction, particularly in the electron transport chain needed for cellular energy production, is an underlying pathophysiological mechanism for some varieties of ASD, clinicians should have a high index of suspicion for mitochondrial disease, especially when they encounter a patient with unusual neurological or constitutional symptoms. The prevalence of mitochondrial disease in ASD patients may be as high as five percent, which means that it is not the “zebra”[27] diagnosis that it might be in a non-ASD patient, where prevalence is about 0.01 percent.10 Reference...
Source: Innovations in Clinical Neuroscience - October 9, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Anxiety Disorders Asperger's syndrome Autism Behavioral and Cognitive Neurology Case Report Current Issue Intellectual Disability Neurologic Systems and Symptoms Pervasive Developmental Disorders ASD autism spectrum disorder dysauton Source Type: research

So you think you can jump? A novel long jump assessment to detect deficits in stroked mice
Conclusions This study introduces a novel assay that can be used to measure a stroke induced behavioral deficit with great sensitivity, and raises interesting questions about potential mechanisms regulating this effect.
Source: Journal of Neuroscience Methods - September 29, 2015 Category: Neuroscience Source Type: research

Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model Basic Sciences
Conclusions— There is a gradient of diminishing responsiveness to motor training over the first week after stroke. Fluoxetine can overcome this gradient and maintain maximal levels of responsiveness to training even 7 days after stroke.
Source: Stroke - September 28, 2015 Category: Neurology Authors: Ng, K. L., Gibson, E. M., Hubbard, R., Yang, J., Caffo, B., O'Brien, R. J., Krakauer, J. W., Zeiler, S. R. Tags: Animal models of human disease, Behavioral Changes and Stroke, Other Stroke Treatment - Medical Basic Sciences Source Type: research

Comparison between herbal medicine and fluoxetine for depression: A systematic review of randomized controlled trials.
CONCLUSIONS: Due to the poor quality of included trials and the potential publication bias of this review, no confirmed conclusion could be draw to evaluate the effectiveness and safety of CHM for depression compared with fluoxetine. PMID: 26365447 [PubMed - in process]
Source: Complementary Therapies in Medicine - September 16, 2015 Category: Complementary Medicine Authors: Ren Y, Zhu C, Wu J, Zheng R, Cao H Tags: Complement Ther Med Source Type: research

Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence
ConclusionIn addition to the need of comprehensive‐clinical evidence, further elucidation of the beneficial mechanisms whereby SSRIs may improve structural and functional recovery from ischemic‐brain damage is needed to form a basis for translation into clinical practice. Several clinical studies have indicated that selective serotonin reuptake Inhibitors (SSRIs) administered after acute ischemic stroke can improve clinical recovery independently of depression. However, data from confirmatory trials in large study populations are lacking and the underlying mechanisms are incompletely understood. This review summarizes...
Source: Brain and Behavior - September 1, 2015 Category: Neurology Authors: Timo Siepmann, Ana Isabel Penzlin, Jessica Kepplinger, Ben Min‐Woo Illigens, Kerstin Weidner, Heinz Reichmann, Kristian Barlinn Tags: Review Source Type: research

Research in mice shows potential value of antidepressant in some stroke victims
Working with mice, researchers have added to evidence that a commonly prescribed antidepressant called fluoxetine helps stroke victims improve movement and coordination, and possibly why.
Source: ScienceDaily Headlines - August 31, 2015 Category: Science Source Type: news

The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials
DiscussionIf fluoxetine is safe and effective in promoting functional recovery, it could be rapidly, widely and affordably implemented in routine clinical practice and reduce the burden of disability due to stroke.Trial registrationFOCUS: ISRCTN83290762 (23/05/2012), AFFINITY: ACTRN12611000774921 (22/07/2011). EFFECTS: ISRCTN13020412 (19/12/2014).
Source: Trials - August 20, 2015 Category: Journals (General) Authors: Gillian MeadMaree HackettErik LundströmVeronica MurrayGraeme HankeyMartin Dennis Source Type: research

Pathological Laughing: Brain SPECT Findings
We present the case of a 40-year-old man consulting for uncontrollable episodes of laughing related to emotional lability and not systematically linked to feelings of happiness. Seven months earlier he had presented a pontine ischemic stroke related to an occlusion of the basilar and left vertebral arteries. No epileptic activity or new MRI brain lesions were found. Brain perfusion SPECT performed showed marked hypoperfusion in the right frontal inferior and temporoinsular regions, suggesting a diaschisis phenomenon caused by pontine lesions and highlighted laughing regulation pathways. The patient was successfully treated...
Source: Clinical Nuclear Medicine - August 11, 2015 Category: Nuclear Medicine Tags: Interesting Images Source Type: research